Skip to search boxSkip to navigationSkip to main content

Induction of Fas (CD95/APO-1) ligand is essential for p53-dependent apoptosis in an in vitro renal carcinoma model system

*Corresponding author for this work
  • The University of Osaka
    ,
  • Walther Cancer Institute
    ,
  • Louisiana State University Health Sciences Center
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Purpose: The Fas/CD95/APO-1 ligand (FasL) is a death cytokine that binds to cell surface Fas/CD95/APO-1 receptor, yet a possible role of FasL expression in p53-dependent apoptosis is not fully understood in many human malignancies, including renal carcinoma. Methods: By Northern blot and Western blot analyses, we determined the effect of p53 on the FasL and Fas receptor expression. To do this, we employed an in vitro renal carcinoma model system that was previously established by stably co-transfecting a temperature-sensitive mutant allele of the p53 tumor suppressor (ts-p53) with either the c-Myc oncogene or adenovirus E1A oncogene in baby rat kidney (BRK) epithelial cells. The ts-p53 is activated only at a permissive temperature. The transactivation activity of p53 was assessed by luciferase reporter assays. The sub-G1 cell population in the cell cycle representing apoptotic cell death was measured by flow cytometric analysis. Results: We found that the level of endogenous FasL, but not Fas receptor, was increased at a permissive temperature with delayed kinetics when compared with p21WAF1 expression, but was coincident with p53-induced apoptosis, whereas an apoptosis-defective mutant p53, which lacks the PxxP region (P: Proline, x: any amino acid), failed to induce FasL expression and hence apoptosis. Notably, p53-induced apoptosis was completely blocked by overexpressing a dominant negative inhibitor of the FADD/Mort-1, a pro-apoptotic adaptor that lies immediately downstream of the FasL/Fas receptor. Conclusions: These results suggest that the FasL is a critical downstream effector of p53-dependent apoptosis in a cultured BRK renal carcinoma model system.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 581-588 (8 pages)

Journal (Volume, Issue Number)

Journal of Cancer Research and Clinical Oncology (Volume 133, Issue 9)

Publication milestones

  • Published - 09/2007

Publication status

Published - 09/2007

ISSN

0171-5216

Publication IDs

  • Scopus: 34447513709
  • PubMed: 17505842

Publication metrics

Metrics

Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
1
Scopus
citations
SciVal
FWCI
0.16
SciVal
Author count
2
SciVal
citations
7
SciVal
Paper percentile
55

PlumX, opens in new tab

Citation count
7
Captures
5

Funding Details

Acknowledgments We thank Drs. D. Green, S. Nagata, B. Vogel-stein, W. El-Deiry, and S. Kaufmann for their plasmid DNAs. We also thank the previous and current members of the Sakamuro laboratory for their suggestion and assistance. This work was supported by grants from the US Army New Investigator Prostate Cancer Research Program (DAMD 17-02-10131), the Wendy Will Case Cancer Fund, the Expedition Inspiration Fund for Breast Cancer Research, the V Foundation for Cancer Research, the Walther Cancer Institute/Purdue Cancer Center Cancer Research Grant, and the Louisiana Cancer Research Consortium Immediate Response Program grant (to D.S.).
FundersFunding number
Louisiana Cancer Research Consortium Immediate Response Program
-
US Army Medical Research and Materiel Command/US Army Research Laboratory
DAMD 17-02-10131
V Foundation for Cancer Research
-
WCF
-
Wendy Will Case Cancer Fund
-